Anebulo lifts lid on midphase cannabis intoxication therapy data, teeing up further development

Anebulo Pharmaceuticals is blazing through a phase 2 clinical trial of anti-cannabinoid intoxication drug candidate ANEB-001, delivering a fresh cut of data that suggests it can counter the effects of higher THC doses.